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Protocol
AbstrACt
Introduction To interrupt malaria transmission, strategies 
must target the parasite reservoir in both humans and 
mosquitos. Testing of community members linked to an 
index case, termed reactive case detection (RACD), is 
commonly implemented in low transmission areas, though 
its impact may be limited by the sensitivity of current 
diagnostics. Indoor residual spraying (IRS) before malaria 
season is a cornerstone of vector control efforts. Despite 
their implementation in Namibia, a country approaching 
elimination, these methods have been met with recent 
plateaus in transmission reduction. This study evaluates 
the effectiveness and feasibility of two new targeted 
strategies, reactive focal mass drug administration (rfMDA) 
and reactive focal vector control (RAVC) in Namibia.
Methods and analysis This is an open-label cluster 
randomised controlled trial with 2×2 factorial design. 
The interventions include: rfMDA (presumptive treatment 
with artemether-lumefantrine (AL)) versus RACD (rapid 
diagnostic testing and treatment using AL) and RAVC 
(IRS with Acellic 300CS) versus no RAVC. Factorial 
design also enables comparison of the combined 
rfMDA+RAVC intervention to RACD. Participants living 
in 56 enumeration areas will be randomised to one of 
four arms: rfMDA, rfMDA+RAVC, RACD or RACD+RAVC. 
These interventions, triggered by index cases detected 
at health facilities, will be targeted to individuals residing 
within 500 m of an index. The primary outcome is 
cumulative incidence of locally acquired malaria detected 
at health facilities over 1 year. Secondary outcomes 
include seroprevalence, infection prevalence, intervention 
coverage, safety, acceptability, adherence, cost and cost-
effectiveness.
Ethics and dissemination Findings will be reported 
on  clinicaltrials. gov, in peer-reviewed publications and 
through stakeholder meetings with MoHSS and community 
leaders in Namibia.
trial registration number NCT02610400; Pre-results.
IntroduCtIon 
There are presently 35 malaria-eliminating 
countries worldwide, making active progress 
towards interruption of domestic transmis-
sion and targeting elimination by 2020–2035.1 
strengths and limitations of this study
 ► The study is among the first to evaluate the 
effectiveness and feasibility of reactive focal 
mass drug administration in a low-transmission/
elimination setting.
 ► The study is the first to evaluate reactive focal indoor 
residual spraying insecticide in a low-transmission/
elimination setting.
 ► The 2×2 factorial design allows for evaluation 
of each intervention individually as well as in 
combination.
 ► The study is nested within the current surveillance 
and response programme of the local Zambezi 
Region Ministry of Health and Social Services, thus 
facilitating potential future integration of strategies 
and creating opportunities for building capacity and 
infrastructure.
 ► The Zambezi Region has been subject to recent 
malaria outbreaks. Such unanticipated shifts in case 
burden may compromise the capacity of the team 
to implement the study interventions which are 
reactive to incident malaria cases.
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As these countries attain low endemicity levels, malaria 
transmission clusters spatially and temporally.2–4 With 
declining transmission, a higher proportion of infected 
individuals remain asymptomatic5–7 and therefore are less 
likely to present for treatment. This infectious reservoir 
can perpetuate transmission8 9 and threaten a country or 
subnational region’s progress towards malaria elimina-
tion. Treating these infections may have a greater effect 
on transmission reduction than focusing exclusively on 
passively detected symptomatic cases.10 Reactive case 
detection (RACD) is a method of actively finding cases 
among the largely asymptomatic household members 
and neighbours of passively identified symptomatic index 
cases. While RACD is widely implemented, there are 
challenges relating to logistics and acceptability of blood 
testing. Also, diagnostics in current use such as micros-
copy and antigen-based rapid diagnostic tests (RDTs) have 
limited sensitivity for asymptomatic infections, which are 
generally of low density.5 9 11–13 There are no controlled 
studies proving the effectiveness of RACD to reduce trans-
mission. As such, the WHO has recommended against the 
use of RACD with currently available diagnostics for trans-
mission interruption.14 
Alternatively, empiric administration of antimalarials 
to an affected population has been recently endorsed 
by WHO as a method to interrupt Plasmodium falciparum 
transmission in low-endemicity settings, where this is likely 
to lead to elimination.14 By circumventing the operational 
and technical challenges of testing, mass drug administra-
tion (MDA) addresses many of the limitations of RACD. 
A systematic review examining the impact of over 180 
published and unpublished MDA programmes showed 
that MDA can successfully eliminate P. falciparum transmis-
sion, though the impact may not be sustained. Interven-
tions showing impact beyond 1 year tended to be in low 
transmission settings and over 80% (10/12) incorporated 
additional vector control.15 There were noted challenges 
reaching high (over 80%) coverage levels due to logistics, 
adherence and acceptability. Acceptability is a particular 
challenge in low transmission settings where community 
members may not perceive malaria as a threat. The safety 
and pharmacovigilance of drug administration to large 
populations is an additional concern as many of those 
treated are uninfected. Targeted drug administration to 
smaller populations of individuals at highest risk of malaria, 
referred to as focal MDA, may mitigate some of the barriers 
and potential harms of untargeted MDA. A reactive focal 
MDA (rfMDA) approach, in which household members 
and neighbours of passively detected index cases are 
targeted, as is done with RACD, has been used successfully 
in low transmission P. vivax settings in China.16 RfMDA 
remains unstudied in P. falciparum endemic, low transmis-
sion areas of sub-Saharan Africa. RfMDA has the additional 
advantage of providing prophylaxis to those members of 
the community who are at highest risk of infection, even if 
they were not infected at the time of treatment.
While providing antimalarial treatment may address 
the human reservoir of parasites, vector control measures 
are necessary to address the mosquito reservoir. Long-
lasting insecticide-treated bed net (LLITN) distribution, 
indoor residual spraying (IRS) of insecticide on the inte-
rior walls of homes, larviciding and community educa-
tion to promote vector avoidance are some commonly 
used approaches. Due to its proven effectiveness17 and 
the seasonal nature of malaria transmission in southern 
Africa, pretransmission IRS is a widely used vector control 
method in the region.18 However, IRS campaigns face 
spray quality and coverage barriers,19 particularly with an 
untargeted ‘blanket’ approach whereby the goal is usually 
to reach at least 80% of sleeping structures in the entire 
endemic area.20 Resistance may also develop if sprayed 
insecticides are not periodically rotated.21 As with strat-
egies targeting the human reservoir, a reactive focal IRS 
using a highly effective insecticide (reactive vector control 
or RAVC) may be an effective, operationally feasible, 
acceptable and cost-saving approach to reducing malaria 
transmission.
Using a cluster randomised controlled design, this study 
seeks to evaluate the effectiveness and feasibility of rfMDA 
and of RAVC, singly and in combination, in comparison 
to standard of care control interventions in the Zambezi 
Region of Namibia. Namibia is a low transmission country 
in southern Africa that, by judicious implementation of 
IRS, LLITNs and effective case management using RDTs 
and artemisinin combination therapies (ACTs), reduced 
incidence from 278 to 9/1000 persons per year between 
200122 and 2011.23 RACD, in conjunction with a single 
yearly round of preseason IRS with dichlorodiphenyltri-
chloroethane or deltamethrin, has remained the back-
bone of the country’s strategic plan to eliminate malaria 
by 2020.24 More recently, the rate of Namibia’s incidence 
decline has plateaued, with outbreaks plaguing the 
northern border. Given the known limitations of RACD 
and untargeted seasonal IRS, new strategies may be 
needed to reach malaria elimination goals.
The antimalarial to be used for rfMDA, as with RACD, 
is the ACT artemether-lumefantrine (AL). AL is safe 
and effective in adult and paediatric populations.25 In 
Namibia, AL is first-line treatment for uncomplicated 
cases caused by P. falciparum, the species comprising 
97% of total malaria infections in the country.24 In addi-
tion to the routine preseason annual IRS administered 
by the national programme, this study will deploy reac-
tive vector control (RAVC) using the microencapsulated 
formulation of the organophosphate pirimiphos-methyl 
(Actellic 300CS; Syngenta AG, Basel, Switzerland). This 
highly effective insecticide has been shown to have 
residual bioactivity on most wall surfaces of up to 12 
months against susceptible mosquitoes,26 a low acute 
toxicity index and is non-teratogenic.27
Aims and objectives
The overall objective of the study is to evaluate the effec-
tiveness and feasibility of two focal, reactive community 
based malaria interventions targeting the parasite reser-
voir in humans and the mosquito, each on its own and in 
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combination, in a partnership with the Namibian Ministry 
of Health and Social Services (MoHSS).
The primary aim is to assess impact of the interven-
tions on cumulative incidence. It is hypothesised that 
rfMDA and RAVC will each be associated with a 50% 
reduction in cumulative incidence compared with RACD, 
and that the combination of rfMDA and RAVC will be 
associated with a 75% reduction compared with RACD 
only, that is, assuming an additive effect with interaction. 
Secondary aims assess effectiveness by comparing sero-
prevalence and infection prevalence between study arms 
in an endline cross-sectional survey. Secondary outcome 
measures of feasibility include coverage, safety, accept-
ability, adherence, cost and cost-effectiveness. The inves-
tigators hypothesise that rfMDA and RAVC will each lead 
to greater reductions of seroprevalence and infection 
prevalence than RACD and show at least equivalent feasi-
bility as RACD.
MEthods And AnAlysIs
The SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials)28 recommendations were 
referenced in developing this protocol.
study design
The study is an open label, cluster randomised controlled 
trial with 2×2 factorial design (table 1) to evaluate the 
superiority of community-based interventions in response 
to a passively identified malaria index case. Factorial 
design allows for comparison of the two study interven-
tions (rfMDA with RAVC) individually, and combined, 
against reference (RACD only). The factorial design 
permits each single intervention to be compared with the 
reference in 2 n clusters per arm, while the combination 
of the two interventions is compared with the reference 
in n clusters per arm. The study design has been gener-
ated through an iterative process of engagement with 
the national and regional MoHSS directorship and with 
Zambezi community leaders.
study setting and trial preparations
More than two-thirds of Namibia’s 2.51 million popula-
tion29 live in its northern malarious regions, characterised 
by low to moderate endemicity. The tropical conditions 
and proximity to Angola and Zambia elevate the risk 
of persistent transmission due to imported malaria.30 31 
Malaria is almost entirely due to P. falciparum.24 Following 
the wet season, the high transmission season typically 
begins in December, peaks between January and April 
and ends in May. The study area is in Zambezi Region, 
located in the northeastern part of the country (figure 1, 
inset) and consists of the catchment areas of 11 health 
facilities in western Zambezi Region (figure 1), covering 
approximately 8000 square km with an estimated popu-
lation of 35 381, based on 2011 census data32 and esti-
mated population growth rate. The Zambezi Region was 
selected as a study site due to having a sufficiently high 
incidence to provide power to answer the study questions, 
while still representing a very low transmission epidemi-
ology, defined by WHO as areas with an annual parasite 
incidence of fewer than 100 cases per 1000 population.33
Table 1 2×2 factorial study design showing four arms
Reactive and targeted strategies addressing human reservoir
RACD*
2 n clusters
rfMDA†
2 n clusters
Reactive and targeted 
strategies addressing 
mosquito reservoir
No RAVC
2 n clusters
RACD only arm
n clusters
rfMDA only arm
n clusters
RAVC‡
2 n clusters
RACD+RAVC arm
n clusters
rfMDA+RAVC arm
n clusters
*RACD: administering rapid diagnostic test to individuals living in a 500 m radius around an index case; treating positives with artemether-
lumefantrine.
†rfMDA: presumptively treating individuals living in a 500 m radius around an index case using artemether-lumefantrine, without testing.
‡RAVC: spraying long-acting insecticide Actellic 300CS to interior walls of living structures of individuals sleeping in a seven household radius 
around an index case.
RACD, reactive case detection; RAVC, reactive vector control; rfMDA, reactive focal mass drug administration. 
Figure 1 Study area in western Zambezi Region, 
Namibia, showing intervention areas and non-study 
areas. RACD, reactive case detection; RAVC, reactive vector 
control. 
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Prior to the trial, various activities were undertaken 
to facilitate study implementation and gather baseline 
epidemiological data. A geographic reconnaissance (GR) 
survey was conducted to geolocate and assign all sleeping 
structures in the study area with a unique GR code. A 
sticker with the GR code was placed in the doorway of 
each sleeping structure and in the health passports of all 
residents. A tablet-based system for rapid reporting of 
malaria cases and their GR code was established in study 
health facilities. A centralised spatial decision support 
system (SDSS)34 was also established to receive data from 
the rapid reporting system and facilitate spatial planning 
for the study interventions. Paper-based malaria registers 
from western Zambezi health facilities for 2013 and 2014 
were reviewed to calculate annual baseline incidences to 
the level of the village. Incidence data from 2015 were 
not available at the time of study planning because 
of transition to the newly established rapid reporting 
system, which was used to capture 2016 incidence data. 
A cross-sectional survey was conducted in the catchment 
areas of six randomly selected health facilities during 
April to June 2015 to measure prevalence of infection 
as well as coverage of interventions such as bed nets, 
preseason IRS and access to healthcare. In 2016, coverage 
of the annual preseason IRS was monitored using mSpray 
technology.35 Community sensitisation took place prior 
to the trial launch and consisted of meeting with MoHSS 
regional leadership and engaging with local community 
leaders, health workers and villagers in meetings and via 
radio announcements.
randomisation
The unit of randomisation is a census enumeration area 
(EA). Of 102 EAs in the study area, 56 were selected for 
inclusion in the trial, excluding EAs without incident 
cases in the prior 3 years. These clusters were randomly 
allocated by computer-generated algorithm to one of four 
arms (figure 1) using restricted randomisation to balance 
the distribution of key characteristics across study arms, 
including EA level incidence in 2013 and 2014, popu-
lation size, population density and healthcare access as 
measured by mean household distance to a health facility. 
A set of 100 000 reassignments meeting the restriction 
criteria was generated. A set of 10 allocations meeting the 
restriction criteria was randomly selected by computer 
algorithm. The final allocation was randomly selected by 
local MoHSS staff.
Procedures
Index case enrolment at health facility
Index case enrolment and subsequent procedures are 
shown (figure 2). Each study intervention will be trig-
gered by an index case diagnosed by RDT (CareStart 
Malaria HRP2/pLDH(Pf/PAN) Combo, Access Bio, 
Somerset, New Jersey, USA) or microscopy36 at one of the 
11 study health facilities and reported through the rapid 
reporting tablets. Index cases detected at the regional 
referral hospital or five private health clinics may also 
trigger a study intervention, with these cases reported 
via a telephone call to study staff or detected through 
weekly visits by study staff. Health facility staff will admin-
ister the MoHSS case investigation form to RDT positive 
index cases and obtain consent for a second pretreatment 
fingerprick to collect a dried blood spot (DBS) for subse-
quent confirmatory molecular testing. This questionnaire 
will include basic information such as demographics, 
occupation, travel, use of vector control interventions, 
recent treatment, GR code and village of residence if GR 
code not available. The health facility worker will notify 
the index case that a team may visit their home to conduct 
an additional questionnaire and offer malaria interven-
tions to household members and neighbours. RDT-posi-
tive cases will be provided with antimalarial treatment at 
the health facility per national guidelines.36
Enrolment of participants for study intervention
For index cases meeting criteria to trigger a response 
(table 2), their household and neighbours will be 
eligible for the study intervention. Using output 
from the SDSS to plan the intervention, a study team, 
consisting of a field investigator, nurse and driver/
data collector, will be dispatched to the home of the 
index case. In the event that there are more pending 
intervention events than available study staff, index 
cases in villages with the highest incidence will 
be prioritised. After establishing contact with the 
village headman, the study team will investigate the 
index case, consisting of: verification of information 
collected in the rapid reporting system; additional 
questions regarding occupation, travel history and use 
of vector control interventions; capture of GPS coordi-
nates and collection of DBS if not drawn at the health 
facility. Study teams will then enrol eligible individ-
uals (table 2) in the target area and deploy the inter-
vention to which the associated EA had been assigned. 
For rfMDA and RACD, the target area consists of the 
index case household and surrounding households 
within 500 m, with a minimum enrolment of 25 indi-
viduals. If fewer than 25 consenting participants live 
within 500 m of the index case, enrolment will stop at 
this distance for that target area. For RAVC, the target 
area will encompass the seven households in closest 
proximity to the home of the index case, including the 
index case household. Given malaria risk is associated 
with proximity to an index case household,3 37 38 study 
teams will approach households with progressively 
increasing distance from the index household. In 
order to maximise enrolment and coverage, teams will 
visit each target area at least twice, at different times 
of the day and preferably within two and no longer 
than 5 weeks of the index case presentation date. On 
the second visit, the team will first revisit households 
with previously missed residents, prior to moving on to 
the next closest household from the index case house-
hold. Prior to approaching individuals within each 
household, a household level questionnaire will be 
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conducted with the household head or their represen-
tative to determine the household size, demographic 
characteristics of household members, construc-
tion materials of the home, coverage of LLITNs and 
preseason IRS and to develop a next-visit plan to enrol 
individuals not present that day.
Reactive case detection
A questionnaire similar to that used in routine index 
case investigation will be administered to all eligible 
consenting individuals in a private area where possible 
in order to maintain confidentiality. Blood will be 
collected by fingerprick for CareStart Pf/PAN RDT and 
Figure 2 Flow of study procedures.
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DBS. Any participant found to be RDT positive will be 
assessed for antimalarial eligibility (table 2) and treated 
with AL for uncomplicated cases. Beginning October 
2016, the MoHSS introduced single low dose primaquine 
for its antigametocidal effect,39 which study nurses will 
administer to participants with uncomplicated malaria. 
Primaquine dosing will be weight banded to approximate 
the target of 0.25 mg/kg and administered in conjunc-
tion with the first AL dose. Exclusion criteria consistent 
with national guidelines36 include pregnancy, age under 
1 year, breastfeeding for 12 months or fewer and allergy 
to primaquine.
Reactive focal mass drug administration
After administration of the same individual-level ques-
tionnaire as in RACD, participants will be screened for 
presumptive antimalarial treatment with AL. Eligible 
participants (table 2) will be weighed and, without 
blood testing, receive two times per day AL (unit doses 
20/120 mg, 40/240 mg, 60/360 mg and 80/480 mg 
for weights 5–14 kg, 15–24 kg, 25–34 kg and ≥35 kg 
respectively), administered 8 hours apart on day 1 and 
12 hours apart on days 2 and 3.
Prior to taking the first AL dose by directly observed 
therapy, each participant will receive instructions on 
self-administration of the remaining five doses and 
will be required to restate correctly the administra-
tion instructions for self and any enrolling minors. 
Participants will be requested to retain AL packaging 
for a potential a return visit pill count. Individuals in 
rfMDA clusters with contraindications to AL (table 2) 
Table 2 Inclusion and exclusion criteria for interventions
Inclusion criteria Exclusion criteria
Index case triggers a 
reactive intervention
 ► Index case with RDT or microscopy confirmed 
malaria identified passively at a study health 
facility
 ► Triggering index case resides (or stayed≥1 night 
within prior 4 weeks) in study enumeration area
 ► Triggering index case diagnosed by active case 
detection
Receipt of test 
(rfMDA or RAVC) 
or control (RACD) 
intervention
 ► Individual resides (or stayed≥1 night within prior 
4 weeks) in study enumeration area within 500 m 
of home of triggering index case (RACD or rfMDA)
 ► Household located in study enumeration area 
among six closest households to triggering index 
case household (RAVC)
 ► Study intervention already implemented in 
individual’s household during the prior 5 weeks 
(RACD or rfMDA)
 ► Study intervention already implemented 
in individual’s household during current 
transmission season (RAVC)
 ► Household sprayed by MoHSS with DDT or 
deltamethrin in the past 24 hours
 ► Household head refusal to participate (RAVC)
 ► Individual level refusal to participate (RACD or 
rfMDA)
 ► Refusal of RAVC is not an exclusion criterion 
for RACD or rfMDA.
 ► Refusal of rfMDA or RACD is not an exclusion 
criterion for RAVC
 AL administration  ►Meets above inclusion criteria for rfMDA or RACD  ► Reported pregnancy in first trimester
 ► Prior regular menstruation followed by 
amenorrhea for most recent 4 weeks and 
refusal of pregnancy testing or positive 
pregnancy testing
 ►Weight under 5 kg
 ► Age under 6 months
 ► Severe/complicated malaria (based on clinical 
assessment)
 ► Prior allergy to AL
 ► Personal history of cardiac dysrhythmia
 ► Family history of long QT syndrome
 ► Regular intake of specified QT-prolonging 
medications*
*Cardiac antiarrhythmic, neuroleptic, tricyclic antidepressant, prokinetic and antiemetic gastrointestinal, second generation antihistamine, 
opioid (methadone) and antimicrobial (macrolide and fluoroquinolone antibiotics, triazole antifungals) agents.
AL, artemether-lumefantrine; DDT, dichlorodiphenyltrichloroethane; MoHSS, Ministry of Health and Social Services; RACD, reactive case 
detection;  RAVC, reactive vector control; RDT, rapid diagnostic test; rfMDA, reactive focal mass drug administration. 
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will be offered RDT testing. RDT-positive individuals 
in all arms with AL contraindications and those with 
severe malaria or other illnesses requiring medical 
attention will be referred to the nearest health facility 
for care. Participants receiving rfMDA will not be given 
primaquine, as effects on safety remain an area of 
ongoing research.40
The first trimester (weeks 0–14) of pregnancy is a 
contraindication to AL per MoHSS national policy.36 
Female participants acknowledging first trimester preg-
nancy will be offered an RDT that, if positive, will result in 
referral to the nearest health facility for alternative treat-
ment with MoHSS-endorsed quinine. Study nurses will 
enquire about menstrual history on all females over 10 
years of age. Postmenarchal females reporting new amen-
orrhea for the preceding 4 weeks will be offered preg-
nancy testing. Refusal of pregnancy testing will constitute 
an AL exclusion and indication for health facility referral.
Reactive vector control
In the RAVC clusters of the study, Actellic 300CS will be 
sprayed on ceilings and walls of all sleeping structures, 
adhering to the national spray application protocol, after 
obtaining consent and requesting residents to reposi-
tion household content. No room containing human or 
animal inhabitants will be sprayed. Teams will instruct 
inhabitants to rinse floors of sprayed structures with 
water before allowing children re-entry and to refrain 
from tampering with sprayed walls until after the malaria 
season. Vector susceptibility to the insecticides used in 
MoHSS preseason IRS and in RAVC as well as residual 
bioefficacy of the insecticide on sprayed walls, will be 
measured as described below.
Pill count
Participants prescribed AL in RACD arms and partici-
pants from one randomly selected target area in each 
rfMDA EA will receive a postintervention follow-up visit 
to assess adherence. At this encounter, the retained 
AL blister packs will be inspected and remaining doses 
recorded. The targeted timing of this pill count visit will 
be 7–10 days after AL was initiated, with a maximum 
30-day interval.
Acceptability assessment
Acceptability will be assessed according to refusal rates 
and questions in the endline survey addressing partici-
pants’ hypothetical willingness to accept the same inter-
vention in the future. A qualitative assessment will also 
be conducted through focus group discussions (FGDs) in 
each study arm, consisting of conseting study participants 
and refusers, in order to assess community acceptability 
of the interventions. Trained facilitators will explore 
positive/negative intervention experiences, reasons for 
opting in/out and perceived malaria risks. FGDs will be 
gender segregated, include youths (15–17 years old) and 
adults separately and exclude community leaders. Indi-
vidual interviews will be held with key informants (KIs) 
consisting of male and female leaders at the village, 
constituency and regional governmental levels. Trained 
interviewers will inquire about the KI’s role in the trial, 
acceptability of the interventions and experience with 
elimination efforts in Namibia. FGDs and KI interviews 
will be audio-recorded with consent.
Endline survey
A cross-sectional endline survey will take place at the end 
of the 2017 transmission season to measure seroprev-
alence and infection prevalence. Study teams will visit 
randomly selected households in each study EA. House-
hold and individual level questionnaires similar to those 
used during the interventions will be administered to 
collect demographic and epidemiological data. A finger-
prick will be used to collect blood for a CareStart Pf/PAN 
RDT test, DBS and 250 uL whole blood in a microtainer 
for subsequent serologic and molecular assays. Treatment 
for CareStart RDT-positive individuals will be provided 
per national guidelines.
Costing and cost-effectiveness assessment
Study teams will compile expenditure data (including 
consumables, equipment and overhead, labour and esti-
mated values of donated goods) from ledgers, budget 
and staff interviews.
Consent
Except for RAVC, for which informed consent will be 
obtained from the household head, all other proce-
dures will require individual level written informed 
consent. Consent will be requested separately for each 
study procedure (eg, questionnaire, blood testing, drug 
administration) and at each encounter (eg, primary study 
interventions, endline cross-sectional survey, acceptability 
assessment). Facilitators will obtain verbal informed 
consent for focus group discussions and KI interviews 
and written consent for all other procedures. Informed 
consent may be collected from all members of a given 
household at once. Consent for minors less than 18 years 
of age will be obtained from a parent or guardian and 
minor assent will also be obtained from participants 
12–17 years old. Informed consent will be conducted 
in SiLozi, the predominant local dialect, or English, the 
national language.
Non-trial care
Participants will be free to seek usual and as-needed 
medical care at their own discretion, with no effect on 
study eligibility or arm allocation. Participants under-
going blood testing or receiving medication(s) or insec-
ticide spraying will receive anticipatory guidance on 
potential side effects. In the event of symptoms, partici-
pants will be instructed to notify the on call study nurse, 
who will be available at all hours and to seek appro-
priate medical care. Study teams encountering individ-
uals with severe or complicated malaria, uncomplicated 
malaria meeting an exclusion criterion for AL, non-fal-
ciparum malaria requiring radical cure or another need 
8 Medzihradsky OF, et al. BMJ Open 2018;8:e019294. doi:10.1136/bmjopen-2017-019294
Open Access 
for further evaluation will refer such participants to the 
nearest health facility.
Entomological monitoring
Susceptibility of the vector population to all four classes 
of insecticide will be assessed at baseline and again at the 
conclusion of the study in each of the four arms. Adult 
Anopheles, reared from larvae and the F-1 progeny of wild 
females, will be tested using standard WHO susceptibility 
tests.41 Mosquitoes will be identified by microscopy and 
the numbers of identified species recorded. Anopheles 
gambiae complex and the An. funestus group will be identi-
fied by PCR.21 WHO cone bioassays42 will be conducted on 
a sample of walls within 1 month of spraying, using insec-
tary reared susceptible mosquitoes. If sufficient mosqui-
toes are found and if there is evidence of resistance, 
samples will be exposed to different concentrations of 
insecticide on filter paper and mortality will be assessed 
24 hours postexposure to obtain LC50 data or exposed to 
the standard WHO diagnostic dose for varying lengths of 
time to estimate LT50s.
Data management
Questionnaires will be programmed using the Open-
DataKit platform,43 with data entered directly into pass-
word-secured tablets. Questionnaires will be coded 
with checks for internal consistency. Data quality will 
be reviewed by data managers with necessary feedback 
communicated to teams in real-time and in weekly meet-
ings. Tablets will be stored in a locked location when not 
in use. Data will be uploaded daily to an encrypted cloud-
based server. Audio-recordings from FGDs will be trans-
lated, transcribed and uploaded into  ATLAS. ti (Scientific 
Software Development GmbH, Berlin, Germany).
To facilitate follow-up visits and linking between data-
sets, data with the exception of transcribed FGDs will 
contain personal identifiers. Only the data managers and 
principal investigators will have access to identified data. 
Data analysts will use anonymised data. On completion of 
the trial and publication of findings, data will be stored 
for at least 5 years in secure databases. Authorised repre-
sentatives of the sponsor, ethics committees or regulatory 
bodies may inspect and audit all documents and records 
on request.
Laboratory methods
All DBS will be collected onto Whatman 3 MM paper 
(Sigma-Aldrich, St. Louis, Missouri, USA), allowed to air 
dry and transported in sealed plastic bags with desiccant. 
These will be stored at 4°C within 24 hours and at −20°C 
within 1 week. DNA will be extracted using the saponin/
Chelex method.44 In light of reports demonstrating faster 
processing time and comparable sensitivity relative to 
conventional PCR,45–47 loop-mediated isothermal ampli-
fication (LAMP) will be used to test samples collected 
in RACD or rfMDA. LAMP will first be performed using 
genus-specific (Pan) primers (Eiken Chemical, Tokyo, 
Japan) followed by P. falciparum-specific primers on 
Pan positive samples. For quality assurance, nested PCR 
targeting the P. falciparum cytochrome b gene48 will be 
performed on all LAMP positive samples and a subset of 
negatives.
To evaluate the secondary outcome of seroprevalence, 
ELISA will be used to measure antimalarial antibody titers 
among individuals in the endline survey. Antibodies will 
be extracted from DBS, and in the case of the endline 
survey from whole blood, using previously described 
methods.49 50 Seroassays will target the blood stage anti-
gens merozoite surface protein 1 and apical membrane 
antigen 1, both validated biomarkers of P. falciparum 
exposure.50 Other antigens sensitive and specific for 
recent exposure are undergoing current evaluation51 
and may also be used. ELISA assays will be performed in 
duplicate and optical densities recorded. Other serologic 
platforms, including fluorescent bead array and protein 
microarray, may be used to analyse responses to multiple 
antigens. To evaluate the secondary outcome of infection 
prevalence, all endline survey samples will undergo an 
ultrasensitive method of P. falciparum-specific quantitative 
PCR,52 using the cell pellet from 100 µL whole blood per 
sample, to measure parasite density.
All molecular and serological assays will be performed 
solely for malaria research purposes and will have no 
impact on the clinical management of study participants.
outcomes and measures
The primary outcome will be cumulative incidence of 
RDT or microscopy confirmed locally acquired cases, 
identified passively at health facilities and reported 
through the rapid reporting system. Determination of 
local acquisition will be based on self-reported lack of 
travel in the previous 8 weeks. Due to the lifecycle of P. 
falciparum in the mosquito and the distribution of distinct 
transmission chains across space and time, an EA level 
impact of the intervention on transmission would not be 
expected for at least several weeks after the first interven-
tion for an EA. Thus, cumulative incidence will be calcu-
lated based on a delayed window of 8 weeks after the first 
index case reported in each study EA during the study 
period. As secondary outcome measures of effective-
ness, seroprevalence will be calculated using ELISA and 
infection prevalence by ultrasensitive quantitative PCR. 
Secondary outcomes of feasibility will include coverage, 
safety, acceptability, adherence, costs and cost-effective-
ness. Further details of outcome measures are outlined 
in table 3.
sample sizes and power calculations
Based on pretrial malaria incidence in 2013 and 2014, the 
study was originally powered for an expected incidence 
of 12.5/1000 persons per year in the RACD arm. Due to 
an unexpected outbreak of malaria cases during the pilot 
phase in 2016, the study team was unable to adhere to 
the protocol of responding to all incident cases in study 
EAs. Staffing was subsequently scaled up and clusters 
restrictively rerandomised as described above. The trial 
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was relaunched in January 2017 for a planned 12 months 
of primary outcome measure data collection. Revised 
power calculations are based on 2016 regional inci-
dence (32.5/1000 persons), study EA total population 
(18,022) and study EA harmonic mean population (276). 
Hypothesised effects on incidence of RACD, rfMDA, 
RAVC and rfMDA+RAVC are 25%, 50%, 50% and 75%, 
respectively. The effective sample size of the population 
is 15 456, predicting 206 enrolled index cases and 5150 
total enrolled individuals. Allowing for refusals (5%) and 
contraindicated interventions due to an antecedent inter-
vention in the prior 5 weeks (10%), a total enrolment of 
4403 individuals is targeted. Using these assumptions and 
sample sizes and a coefficient of variation of 0.95 calcu-
lated from baseline EA level incidence rates, the trial 
will have at least 80% power to detect the hypothesised 
effects of rfMDA versus RACD, RAVC versus no RAVC and 
rfMDA+RAVC versus RACD alone.
The endline survey will sample 25 randomly selected 
households in each study EA. An estimated 6300 sampled 
and 5040 enrolled individuals are anticipated, assuming a 
mean household size of 4 people and 20% non-response. 
With a sample size of 2520 in the two rfMDA arms and 
2520 in the two RACD arms and the same numbers for 
the two RAVC based and two non-RAVC arms, the survey 
will have 80% power to detect a minimum detectable 
decrease in seroprevalence to 5.3% (47% reduction) 
for rfMDA versus RACD and RAVC versus non-RAVC, 
assuming 10% seroprevalence in the RACD arms.50 As 
infection prevalence is expected to be low, power calcula-
tions were not be performed for this secondary outcome 
measure.
With regard to the feasibility evaluation, the trial will 
aim to achieve 80% coverage based on modelling studies10 
and experience from successful presumptive treatment 
programmes15 as well as 80% adherence among subjects 
receiving AL as part of the study intervention. If the 
estimates for incidence and target area population are 
correct, the study will be powered to measure at least 80% 
coverage for the rfMDA, RACD and RAVC interventions 
as well as 80% adherence (Alpha=0.05). Power calcula-
tions were not performed for the safety assessment as few 
to no serious adverse events53 (SAEs) are anticipated. For 
the acceptability assessment, a total of 12 FGDs, three 
per study arm (adult females, adult males and youths) 
consisting of 8–12 participants each, will be conducted 
along with at least six KI interviews. In the costing evalua-
tion, detailed expenditure analysis will be performed for 
10 target areas per study or control intervention.
statistical analysis
One-way frequency tables for all categorical variables and 
distributions, ranges and outliers for continuous variables 
will be generated to perform range checks, quantify the 
amount of missing data and generate descriptive findings 
characterising EA and target area characteristics. These 
Table 3 Method of outcome measurements
Outcome Measurement metrics
Incidence Cumulative incidence of RDT or microscopy confirmed locally acquired cases identified at study 
health facilities
Seroprevalence Prevalence of antibody response to validated Plasmodium  falciparum antigens detected by 
ELISA
Infection prevalence Prevalence of infection detected by ultrasensitive qPCR using whole blood
Intervention level coverage Proportion of index cases for which a study intervention is implemented
Individual level coverage RfMDA: Proportion of rfMDA-eligible residents of target area who take the first dose of AL
RACD: Proportion of RACD-eligible residents of target area who undergo fingerprick for RDT 
testing
RAVC: Proportion of RAVC-eligible households in target area that are sprayed with Actellic 300CS
Safety Frequency of serious adverse events51 deemed possibly, probably or definitely related to study 
intervention
Acceptability Quantitative assessment measured by proportion of eligible individuals who consent to receive 
the assigned intervention and proportion of participants sampled in endline survey who indicate 
they would participate in the intervention again if offered
Qualitative assessment in focus group discussions and key informant interviews
Adherence Among those selected for pill count, proportion of participants found to have completed AL 
course
Cost Cost (materials, labour and infrastructure) per intervention event and per person enrolled, and in 
RACD arms, cost per additional infection found
Cost-effectiveness Cost per case averted and incremental cost effectiveness ratio for rfMDA versus RACD, RAVC 
versus no RAVC and rfMDA+RAVC versus RACD alone (should the test interventions prove to be 
more effective than control)
AL, artemether-lumefantrine; qPCR, quantitative PCR; RACD, reactive case detection; RAVC, reactive vector control; RDT, rapid diagnostic 
test; rfMDA, reactive focal mass drug administration. 
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analyses will be stratified by intervention (ie, rfMDA vs 
RACD and RAVC vs no RAVC). The baseline group 
covariates will be analysed for equality (eg, by Rao-Scott 
χ2). Although we expect randomisation to produce 
balanced covariate structures, we will consider methods 
of adjustment to balance baseline covariates (eg, LLITN 
use, pretransmission season IRS coverage, travel history, 
housing, occupation, ecological factors) should there be 
differences between the arms. If an imbalance is found, 
a second set of models will be run for all primary anal-
yses. Adjusted models will be used to reweight the data, 
either through inverse probability weighting or targeted 
minimum loss based estimation, in order to estimate 
effects based on equally distributed covariates.
Three comparisons of cumulative incidence will be 
made using an intention-to-treat (ITT) approach: rfMDA 
versus RACD arms (28 EAs each), RAVC versus non-RAVC 
arms (28 EAs each) and rfMDA+RAVC versus RACD 
alone (14 EAs each). Outcomes will be assessed at both 
the level of the EA (cluster) and the individual, adjusting 
for clustering. The modelling approach for individual 
level analyses will adjust for observation correlation by 
EA for analyses using the overall sample and by both EA 
and target area for analyses using the target area sample. 
Generalised estimating equations (GEEs) will be used to 
perform the proposed primary analyses. GEE methods 
account for the correlation of persons within clusters and 
EAs. Robust Huber-White ‘sandwich’ SEs will be used to 
obtain correct inferences even if the chosen correlation 
structure remains slightly mis-specified. Alpha will be 
set at 0.05 for all planned comparisons. Primary anal-
yses will follow an ITT model. Individuals will be anal-
ysed according to their randomisation arm regardless 
of received treatment. Additional analyses will consider 
adjustments for variability in intervention timing and 
coverage, differential administration of single low dose 
primaquine in RACD versus rfMDA arms, proximity to 
the nearest household receiving an alternate intervention 
and variation in EA characteristics that differed by inter-
vention arm, including receipt of RAVC and/or rfMDA 
during the pilot phase of the study.
Proportional hazards regression for an individu-
al’s survival to the first episode of malaria will also be 
performed. Individual incident cases registered in 
the rapid reporting system will be tallied by EA. Using 
summary population data from the GR for each EA, the 
number of individuals in each EA who did not have an 
incident case of malaria reported will be calculated and 
a record generated for each hypothesised non-infected 
individual. These will be combined with the records for 
incident cases to create a dataset with one record for each 
individual in every EA. This dataset will be used to run a 
Cox hazard model of time to either incident infection or 
the date of dataset aggregation. The start time for each 
EA will be the date of the first incident infection, that is, 
the index infection that triggered a study intervention. 
Hazard models will adjust for clustering of observations 
by EA. Significance will be calculated using a robust 
‘sandwich’ estimator. To consider different criteria for 
intervention effectiveness, three models will be run: all 
cases postdating the index case; all cases excluding those 
with travel history (ie, presumed imported cases) and 
all cases censoring those with either a travel history or a 
detection date within 8 weeks of the index case.
Although power is limited by the constraints of the 
total number EAs in the study area, summary measures of 
incidence and intervention effects will be described for 
certain subgroups of interest within the study population 
(eg, members of each gender, children and those living in 
highest-incidence geographic areas).
Secondary outcome measures will be assessed descrip-
tively or as appropriate, using GEE techniques to account 
for the clustered nature of the data collection. For the 
qualitative analysis, transcripts of FGDs and KI interviews 
will be coded in ATLAS.ti5. Major themes will be identi-
fied by two members of the study team independently. 
Any discrepancies will be resolved by inviting a third 
member of the study team to verify findings. Data will 
then be analysed to provide a description of the barriers 
and facilitators to acceptance. For the costing assess-
ment, calculations will include total costs of the study 
interventions, costs per intervention event and cost per 
individual enrolled. For the cost-effectiveness assessment, 
the main outcome measures will be cost per case averted 
and incremental cost effectiveness ration, should the test 
interventions prove to be more effective than the control 
interventions.
EthICs And dIssEMInAtIon
Monitoring, harms and auditing
After initial training, each study team will continue to 
undergo regular evaluation and supervision of its enrol-
ment and intervention activities, by the Site Manager, 
Research Manager and designated team leaders, to ensure 
compliance with study protocol. The Data Manager and 
Research Manager will carry out weekly internal audits of 
completed questionnaires and case investigation records 
to ensure high-quality data capture and provide team 
member feedback.
Prior to launch, trainings will be held at each study 
health facility to educate staff on the study interventions 
and on the spectrum of potential toxicities due to AL, 
Actellic 300CS and in the event of national rollout, single 
low dose primaquine. In addition to passive pharmacovig-
ilance, study nurses will proactively inquire about symp-
toms among participants during return visits to a target 
area for further enrolment or pill counts. Study nurses will 
review all SAEs within 48 hours and perform a follow-up 
visit within 72 hours in conjunction with the study physi-
cian. The physician will assign causality, recommend 
retention versus exclusion from the study and report 
the SAE to the investigators. All SAEs will be reported 
to the Data and Safety Monitoring Board (DSMB) and 
to the MoHSS Therapeutics Information and Pharma-
covigilance Center in Windhoek, Namibia, within 7 days 
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of occurrence. Reports of all SAEs classified as possibly, 
probably or definitely related to a study intervention, as 
well as of all suspected unexpected serious adverse reac-
tions (SUSARs), will be submitted to the institutional 
review boards of the participating institutions, within 
7–10 days of occurrence or per the boards’ stipulations.
The DSMB will consist of at least four content experts 
in malaria elimination, clinical trial design and pharma-
cology who did not contribute to the study’s design and 
are independent of the project’s operations and external 
to the investigators’ institutions. The DSMB will review 
the protocol and analytical plan prior to launch. During 
the study, the DSMB will examine SAE and SUSAR reports 
and have final authority on such participants’ continu-
ation versus withdrawal from the study. The DSMB will 
meet every 3–4 months to review trial safety and enrol-
ment data and vote to recommend trial continuation 
versus early termination. Stopping guidelines will be 
based on the prevalence of SAEs deemed to have a causal 
association with the study interventions as well as enrol-
ment and consequent likelihood of endpoint assessability.
The study’s Steering Committee will consist of senior 
representatives of the MoHSS, University of Namibia, 
University of California, London School of Hygiene and 
Tropical Medicine, Clinton Health Access Initiative and 
Novartis Foundation and will provide technical oversight 
of the study. The Committee will assist with interpretation, 
dissemination and extrapolation of findings for interna-
tional impact while ensuring consistency with MoHSS 
goals for elimination. The Committee will meet once 
yearly in Namibia, participate in teleconferences one to 
two additional times a year and have ongoing interactions 
with study team members on an as needed basis.
dissemination
Study findings will be shared in stakeholder meetings 
attended by regional and national MoHSS representa-
tives, with health facility staff and community leaders, 
through peer-reviewed publications and at scientific 
conferences. Results will also be reported on the Web 
through  clinicaltrials. gov.
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